A first pregnancy is always a deeply anticipated milestone for every couple. However, this profound joy can swiftly turn into devastating grief if a miscarriage occurs, particularly when facing the heartbreak of recurrent pregnancy loss. Within society, it is a very common misconception to immediately blame parasitic infections like Toxoplasma as the sole culprit behind pregnancy failure. Yet, from an immunological perspective, there is a hidden factor that is frequently overlooked: a blood-thickening autoimmune condition known as Antiphospholipid Syndrome (APS). 

Medically, Antiphospholipid Syndrome is an autoimmune disorder where the body mistakenly produces abnormal antibodies. These autoantibodies actively target the vascular lining and the placental tissue, which functions as the vital life support system supplying nutrients and oxygen to the developing fetus. Consequently, this interaction induces endothelial damage, culminating in localized thrombosis or blood clotting within the placenta. This restricted blood flow heavily compromises trophoblast function and placental development, ultimately triggering recurrent early miscarriages during the first trimester. 
To prevent ongoing pregnancy loss, accurate and early medical screening is absolutely essential. The cornerstone for identifying the presence of these harmful autoantibodies is undergoing the ACA (Anticardiolipin Antibody) IgG/IgM Test. This specific laboratory evaluation allows healthcare professionals to precisely measure both IgG and IgM anticardiolipin antibody titers in the bloodstream. Detecting high-risk antibody profiles early empowers physicians to formulate tailored management plans, such as targeted anticoagulant therapies, ensuring a safer journey toward a successful live birth.